Chemomab Therapeutics Overview
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study in patients with severe lung injury. A global Phase 2 trial in primary sclerosing cholangitis patients is ongoing, with a top-line data readout targeted for the second half of 2024.
Cumulative Funding Raised Over Time ($)
$10.0MDec 2017
$30.0MDec 2019
$40.0MJul 2024
$85.5MMar 2021
$90.5MSep 2016
$90.5MSep 2021
Latest News
growth-positive
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes plc has announced a definitive agreement to acquire Avadel Pharmaceuticals in a deal valued at approximately $2.1 billion, expected to close in the first quarter of 2026. The acquisition will be funded through Alkermes existing cash reserves and new debt issuance. Avadels lead product, Lumryz, is approved for treating narcolepsy and has shown significant sales growth. The acquisition will allow Alkermes to enter the sleep medicine market and complement its current pipeline, including the development of alixorexton for narcolepsy and idiopathic hypersomnia. The deal includes a contingent value right dependent on FDA approval of Lumryz for idiopathic hypersomnia by 2028.
Acquisition
growth-positive
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi announced positive results from its phase II ElevAATe study for efdoralprin alfa, a treatment for alpha-1 antitrypsin deficiency (AATD) emphysema. The study met all primary and key secondary endpoints, demonstrating significant improvements in functional AAT levels compared to existing therapies. Efdoralprin alfa, acquired through Sanofis acquisition of Inhibrx in 2024, offers a more convenient dosing regimen and has received fast track and orphan drug designations from the FDA. This development highlights Sanofis potential to improve treatment options for AATD patients. Year-to-date, Sanofis shares have increased by 3%, reflecting positive market sentiment.
Product StageAcquisition
growth-positive
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion Therapeutics has nominated ESP-2001, a specific allosteric ATP citrate lyase inhibitor, as a preclinical candidate for treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease. The company plans to initiate IND-enabling studies and submit an IND application to the FDA, aiming to start clinical studies in 2026. The nomination was part of a collaboration with Evotec, which involved an undisclosed payment. ESP-2001 has shown promise in preclinical studies and could qualify for Orphan Drug and Fast Track designations. Esperions stock rose 5.2% following the announcement, and the company has two FDA-approved drugs, Nexletol and Nexlizet, for cardiovascular conditions.
Product StagePartnersFDA approved/pending approval
growth-positive
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Viatris announced the acquisition of Aculys Pharma, a Tokyo-based clinical-stage biopharmaceutical company specializing in neurological therapies. This acquisition grants Viatris the rights to develop and commercialize pitolisant and Spydia (diazepam nasal spray) in the Central Nervous System (CNS) segment. The deal involves an undisclosed upfront payment and additional milestone-based payments. Viatris aims to strengthen its CNS portfolio and expand its presence in Japan and the Asia-Pacific region. Pitolisant, already FDA-approved in the US, is planned for marketing approval in Japan by 2025. Spydia Nasal Spray, approved in Japan for status epilepticus, adds to Viatris pipeline for neurological emergencies.
Acquisition
growth-positive
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals announced that the FDA has accepted their resubmitted biologics license application (BLA) for Kresladi, a gene therapy aimed at treating severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The FDAs decision is expected by March 28, 2026. The acceptance of the BLA is based on positive data from a global phase I/II study, which demonstrated 100% overall survival for LAD-I patients at 12 months post-infusion. If approved, Rocket Pharmaceuticals will be eligible for a Rare Pediatric Disease Priority Review Voucher. The companys shares rose by 23.1% following the announcement, although they have decreased by 66.1% year-to-date. This potential approval would mark Rockets first commercial product, providing a new revenue stream.
Product StageFDA approved/pending approval
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $90.5M |
| Last funding | $10M |
| Stage | Public |
| Rounds | 7 |
| Investors | 12 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | chemomab.com |
Locations
Kiryat Atidim, Tel Aviv-Yafo, Israel
Photos & Videos
1 item(s)
Chemomab Therapeutics Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsCore Technology
BiologicalsTags (9)
pharmaceuticalsautoimmune-diseasesimmunologydrug-deliverydrug-discoveryhealthcare-providerstreatmentsantibodiesbiopharmaceuticalGeographic Markets
GlobalChemomab Therapeutics Financials
$90.5M
Total funding
Undisclosed
Capital raised
$10M
Last funding
Public
Funding stage
7
Total rounds
12
Investors
Cumulative Funding Raised Over Time ($)
$10.0MDec 2017
$30.0MDec 2019
$40.0MJul 2024
$85.5MMar 2021
$90.5MSep 2016
$90.5MSep 2021
Private Equity Funding
PIPE
Jul 2024
$10M
OrbiMed, Sphera Global Healthcare Fund, HBM Healthcare Investments
PIPE
Sep 2021
Undisclosed
Shavit Capital Fund
PIPE
Mar 2021
$45.5M
Cormorant Asset Management (Lead)
,
Apeiron Investment Group, Presight Capital, Peter Thiel, OrbiMed
C Round
Dec 2019
$20M
Milestone Venture, Presight Capital, SBI JI Innovation Fund, OrbiMed, Peter Thiel, Finteca Holdings, Boryung Pharmaceuticals
B Round
Dec 2017
$10M
Peter Thiel, Milestone Venture, OrbiMed, SBI JI Innovation Fund
A Round
Sep 2016
$5M
OrbiMed
Non-Equity Funding
GrantEvent
Undisclosed
OSC
Public Offering / Exit
ReverseMergerEvent
Mar 2021
Undisclosed
Mergers & Acquisitions
MNAEvent
Mar 2021
Undisclosed
Chemomab Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$10.0MDec 2017
$30.0MDec 2019
$40.0MJul 2024
$85.5MMar 2021
$90.5MSep 2016
$90.5MSep 2021
All Events
PIPE
Jul 2024
$10M
OrbiMed, Sphera Global Healthcare Fund, HBM Healthcare Investments
PIPE
Sep 2021
Undisclosed
Shavit Capital Fund
PIPE
Mar 2021
$45.5M
Cormorant Asset Management (Lead)
,
Apeiron Investment Group, Presight Capital, Peter Thiel, OrbiMed
C Round
Dec 2019
$20M
Milestone Venture, Presight Capital, SBI JI Innovation Fund, OrbiMed, Peter Thiel, Finteca Holdings, Boryung Pharmaceuticals
B Round
Dec 2017
$10M
Peter Thiel, Milestone Venture, OrbiMed, SBI JI Innovation Fund
A Round
Sep 2016
$5M
OrbiMed
GrantEvent
Undisclosed
OSC
ReverseMergerEvent
Mar 2021
Undisclosed
MNAEvent
Mar 2021
Undisclosed
Chemomab Therapeutics News
107 articles
growth-positive
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes plc has announced a definitive agreement to acquire Avadel Pharmaceuticals in a deal valued at approximately $2.1 billion, expected to close in the first quarter of 2026. The acquisition will be funded through Alkermes existing cash reserves and new debt issuance. Avadels lead product, Lumryz, is approved for treating narcolepsy and has shown significant sales growth. The acquisition will allow Alkermes to enter the sleep medicine market and complement its current pipeline, including the development of alixorexton for narcolepsy and idiopathic hypersomnia. The deal includes a contingent value right dependent on FDA approval of Lumryz for idiopathic hypersomnia by 2028.
Acquisition
growth-positive
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi announced positive results from its phase II ElevAATe study for efdoralprin alfa, a treatment for alpha-1 antitrypsin deficiency (AATD) emphysema. The study met all primary and key secondary endpoints, demonstrating significant improvements in functional AAT levels compared to existing therapies. Efdoralprin alfa, acquired through Sanofis acquisition of Inhibrx in 2024, offers a more convenient dosing regimen and has received fast track and orphan drug designations from the FDA. This development highlights Sanofis potential to improve treatment options for AATD patients. Year-to-date, Sanofis shares have increased by 3%, reflecting positive market sentiment.
Product StageAcquisition
growth-positive
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion Therapeutics has nominated ESP-2001, a specific allosteric ATP citrate lyase inhibitor, as a preclinical candidate for treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease. The company plans to initiate IND-enabling studies and submit an IND application to the FDA, aiming to start clinical studies in 2026. The nomination was part of a collaboration with Evotec, which involved an undisclosed payment. ESP-2001 has shown promise in preclinical studies and could qualify for Orphan Drug and Fast Track designations. Esperions stock rose 5.2% following the announcement, and the company has two FDA-approved drugs, Nexletol and Nexlizet, for cardiovascular conditions.
Product StagePartnersFDA approved/pending approval
growth-positive
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Viatris announced the acquisition of Aculys Pharma, a Tokyo-based clinical-stage biopharmaceutical company specializing in neurological therapies. This acquisition grants Viatris the rights to develop and commercialize pitolisant and Spydia (diazepam nasal spray) in the Central Nervous System (CNS) segment. The deal involves an undisclosed upfront payment and additional milestone-based payments. Viatris aims to strengthen its CNS portfolio and expand its presence in Japan and the Asia-Pacific region. Pitolisant, already FDA-approved in the US, is planned for marketing approval in Japan by 2025. Spydia Nasal Spray, approved in Japan for status epilepticus, adds to Viatris pipeline for neurological emergencies.
Acquisition
growth-positive
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals announced that the FDA has accepted their resubmitted biologics license application (BLA) for Kresladi, a gene therapy aimed at treating severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The FDAs decision is expected by March 28, 2026. The acceptance of the BLA is based on positive data from a global phase I/II study, which demonstrated 100% overall survival for LAD-I patients at 12 months post-infusion. If approved, Rocket Pharmaceuticals will be eligible for a Rare Pediatric Disease Priority Review Voucher. The companys shares rose by 23.1% following the announcement, although they have decreased by 66.1% year-to-date. This potential approval would mark Rockets first commercial product, providing a new revenue stream.
Product StageFDA approved/pending approval
growth-negative
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Tvardi Therapeutics experienced a significant stock drop of 83.9% following disappointing results from a phase II study of its lead candidate, TTI-101, for treating idiopathic pulmonary fibrosis (IPF). The study, which included 88 patients, aimed to evaluate safety, pharmacokinetics, and lung function but failed to meet its primary objectives. TTI-101 did not show a meaningful benefit over placebo, and the study was not statistically powered to assess exploratory efficacy outcomes. Discontinuation rates were higher in the TTI-101 groups, primarily due to gastrointestinal adverse events. The companys stock has fallen 63.6% year-to-date, contrasting with the industrys growth.
Product Stage
growth-positive
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics announced that its lead pipeline candidate, CD388, has received Breakthrough Therapy designation from the FDA for the prevention of seasonal influenza. This designation is intended to expedite the development and review of drugs that show potential for significant improvement over existing treatments. CD388, developed using Cidaras Cloudbreak platform, is a long-acting small molecule inhibitor targeting influenza. The decision was based on positive phase IIb study data showing significant prevention of influenza. The company has initiated a phase III study, which could support regulatory filing if successful. Shares of Cidara Therapeutics rose 12.4% following the announcement, and the stock has increased by 312% year-to-date.
Product StageFDA approved/pending approval
growth-positive
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics shares surged by 39.2% following positive top-line data from a phase I study of its lead investigational candidate, OV329. This next-generation GABA-AT inhibitor is being developed to treat rare and drug-resistant epilepsies. The study involved 68 healthy volunteers and evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of OV329. Results showed significant GABAergic activity, with OV329 demonstrating superior inhibitory effects compared to the benchmark GABA-AT inhibitor, vigabatrin. The study also reported increased brain GABA levels and enhanced inhibitory brainwave activity, reinforcing OV329s potential as a novel treatment for refractory epilepsy.
Product Stage
growth-positive
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AstraZeneca announced positive results from the phase III Bax24 study, which evaluated the safety and efficacy of baxdrostat in patients with resistant hypertension. The study showed that baxdrostat significantly reduced systolic blood pressure compared to placebo, with efficacy observed over a 24-hour period. The treatment was well tolerated, with a safety profile similar to previous studies. AstraZeneca plans to share these results with global regulatory authorities. The company has seen a 31.1% increase in shares year-to-date, outperforming the industry average. Baxdrostat is also being investigated for other conditions, including primary aldosteronism and chronic kidney disease.
Product Stage
growth-negative
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
KALA BIOs shares have dropped significantly following the failure of a phase IIb study for its clinical candidate, KPI-012, aimed at treating persistent corneal epithelial defect (PCED). The study did not meet its primary or secondary endpoints, leading the company to discontinue the development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform. This setback reverts KALA BIO to the preclinical stage, delaying its product advancement and revenue generation prospects. The company plans to explore strategic alternatives and implement cost-control measures, including workforce reductions. This marks a significant blow to KALA BIO, which had high hopes for KPI-012 as a key value driver.
Product StageLayoffs
growth-positive
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Chemomab Therapeutics, a clinical stage biotechnology company, is advancing its innovative therapeutics for fibro-inflammatory diseases. The company announced that its CEO, Dr. Adi Mor, will present at the H.C. Wainwright 27th Annual Global Investment Conference. Chemomab is developing nebokitug (CM-101), a monoclonal antibody targeting CCL24, which has shown promise in treating severe fibro-inflammatory diseases. The company is preparing for a Phase 3 trial for primary sclerosing cholangitis (PSC) following positive Phase 2 results. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations. Chemomab will also engage in investor meetings during the conference.
Product StageInvestment
growth-positive
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics is advancing its Phase 3 program for nebokitug, a treatment for primary sclerosing cholangitis (PSC), and is actively seeking strategic partners to optimize development and commercialization. The company has aligned with the FDA on regulatory requirements and is planning a global Phase 3 trial. Chemomab has expanded its patent portfolio in China and Russia, enhancing its potential for future commercialization. The company aims to secure a partner to accelerate the Phase 3 launch and maximize nebokitugs commercial potential. Financially, Chemomab has a cash runway through the second quarter of 2026.
Product StagePartners
growth-positive
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
Chemomab Therapeutics announced positive results from its Phase 2 SPRING trial of nebokitug (CM-101) for treating primary sclerosing cholangitis (PSC). The data, presented at the BSG Live’25 conference, showed that nebokitug is well-tolerated and associated with significant improvements in fibrotic and inflammatory biomarkers, suggesting its potential as a disease-modifying treatment. The trials findings support advancing nebokitug to a Phase 3 registration trial. The study demonstrated that nebokitug had a safety profile comparable to placebo and showed dose-dependent anti-inflammatory and anti-fibrotic effects. These results are promising for patients with moderate to advanced PSC, indicating sustained improvements in disease markers.
Product Stage
growth-positive
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
Chemomab Therapeutics has achieved significant regulatory milestones with the FDA for its drug nebokitug, aimed at treating primary sclerosing cholangitis (PSC). The FDA has agreed with Chemomabs Chemistry, Manufacturing, and Controls (CMC) strategy and allowed toxicology testing to proceed in parallel with the Phase 3 clinical trial. This flexibility supports the timely advancement of the program. Chemomab is also in discussions with potential strategic partners to further the development of nebokitug, which has shown promising results in previous clinical trials. The drug has received FDA and EMA Orphan Drug designations and FDA Fast Track status, highlighting its potential to address unmet medical needs.
Product StagePartners
growth-positive
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Chemomab Therapeutics announced new patent protections for its lead product, nebokitug, in China and Russia, extending coverage up to 2041. These patents enhance the companys intellectual property portfolio, reinforcing its strategic position in treating primary sclerosing cholangitis (PSC). The company is advancing partnerships to support a Phase 3 trial in PSC, following positive Phase 2 results. The FDA has aligned on a regulatory approval pathway for PSC, marking a significant milestone. Chemomab is focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet needs.
Product StagePartners
growth-positive
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics announced positive 48-week data from its SPRING trial for the treatment of primary sclerosing cholangitis (PSC) using Nebokitug. The company has aligned with the FDA on a regulatory pathway for potential approval, advancing Nebokitug to Phase 3 trials. The data showed significant improvements in key biomarkers of liver injury, inflammation, and fibrosis, positioning Nebokitug as a potential first FDA-approved treatment for PSC. Chemomab is exploring multiple partnering options to execute the Nebokitug program and has extended its cash runway to the second quarter of 2026.
Product StageFDA approved/pending approvalPartners
growth-positive
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
Chemomab Therapeutics presented promising data from its Phase 2 SPRING trial of nebokitug (CM-101) at Digestive Disease Week 2025. The trial, targeting primary sclerosing cholangitis (PSC), showed that nebokitug is well-tolerated and associated with significant improvements in fibrotic and inflammatory biomarkers over 48 weeks. These findings suggest nebokitugs potential as a disease-modifying treatment, supporting its advancement to a Phase 3 clinical study. The data indicated dose-dependent anti-inflammatory and anti-fibrotic effects, with patients showing sustained improvements in biomarkers and stabilization of liver stiffness. The results are encouraging for the development of nebokitug as a first-in-class treatment for PSC, a disease with no FDA-approved therapies.
Product Stage
growth-positive
Biotech Alert: Searches spiking for these stocks today
Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases. Their lead product, nebokitug, is a monoclonal antibody targeting the soluble protein CCL24, which plays a role in fibrosis and inflammation. Nebokitug has shown promise in clinical trials, demonstrating a favorable safety profile and potential to treat severe fibro-inflammatory diseases. The company is preparing for a Phase 3 trial for primary sclerosing cholangitis (PSC), following positive Phase 2 results. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. This article highlights the growth potential of Chemomab Therapeutics, as well as other biotech companies experiencing increased interest.
Product StageFDA approved/pending approval
growth-positive
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
Chemomab Therapeutics has reported promising data from its Phase 2 SPRING trial for nebokitug (CM-101), a treatment for primary sclerosing cholangitis (PSC) and other fibro-inflammatory diseases. The trial results, to be presented at EASL 2025, show significant improvements in inflammatory and fibrotic biomarkers, indicating nebokitugs potential as a first-in-class treatment. The comprehensive proteomic analyses revealed dose-dependent changes in proteins related to fibrosis and inflammation, providing new insights into PSC disease pathways. The treatment was associated with downregulation of processes related to fibrosis and inflammation, highlighting its clinical potential.
Product Stage
growth-positive
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
Chemomab Therapeutics, a clinical-stage biotechnology company, is set to present clinical data on its monoclonal antibody, CM-101, at several major scientific conferences in 2025. CM-101 is being developed for the treatment of primary sclerosing cholangitis (PSC), a fibro-inflammatory disease. The presentations will cover the safety, tolerability, and efficacy of CM-101, highlighting improvements in biomarkers related to inflammation, fibrosis, and cholestasis. The data will be shared at Digestive Disease Week 2025 in San Diego, the European Association for the Study of the Liver Congress in Amsterdam, and the British Society of Gastroenterologys annual meeting in Glasgow. These presentations are expected to enhance Chemomabs visibility and potentially attract interest from the scientific community and investors.
Product Stage
growth-positive
Chemomab Announces New Medical and Clinical Appointments
Chemomab Therapeutics, a clinical-stage biotechnology company, announced key management changes with the appointment of David M. Weiner, MD, as Interim Chief Medical Officer and Jack Lawler as Chief Development Officer. Dr. Weiner, who has extensive experience in drug development, returns to Chemomab after previously serving as Interim CMO and consultant. Jack Lawler, who played a crucial role in the successful completion of the Phase 2 SPRING trial for primary sclerosing cholangitis (PSC), will now oversee development operations. These changes come as Chemomab plans its next steps following the positive results of the Phase 2 trial. The company focuses on developing therapeutics for fibro-inflammatory diseases with high unmet needs.
Management ChangesProduct Stage
growth-positive
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Chemomab Therapeutics announced positive results from the Open Label Extension (OLE) portion of their Phase 2 SPRING trial for nebokitug, a treatment for primary sclerosing cholangitis (PSC). The trial showed significant improvements in key biomarkers of liver injury, inflammation, and fibrosis over 48 weeks, reinforcing the potential of nebokitug as a disease-modifying drug for PSC. The results derisk the planned Phase 3 clinical trial and provide further clinical proof-of-concept. The treatment was well-tolerated, with more than 90% of eligible patients opting to continue in the OLE. The findings are particularly promising for patients with moderate to advanced PSC, who are at higher risk for disease progression.
Product Stage
growth-positive
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
Chemomab Therapeutics, a clinical-stage biotechnology company, has announced new scientific findings supporting the potential of nebokitug (CM-101) as a treatment for systemic sclerosis (SSc). The data, to be presented at the CORA 2025 conference, highlights nebokitugs ability to block the protein CCL24, a key driver in fibro-inflammatory conditions like SSc. Preclinical studies and an investigator-sponsored study have shown promising results in reducing inflammatory and fibrotic injury in SSc patients. The company has an open U.S. IND for a Phase 2 trial of nebokitug in SSc. The study was conducted in collaboration with Dr. Alexandra Balbir-Gurman and utilized patient samples and data from a mouse model to further understand nebokitugs effects.
Product Stage
growth-positive
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
Chemomab Therapeutics announced successful outcomes from its FDA End-of-Phase 2 meeting following positive results from its Phase 2 SPRING trial for nebokitug in treating Primary Sclerosing Cholangitis (PSC). The company achieved alignment with the FDA on a clear pathway to regulatory approval, with no liver biopsies or confirmatory studies needed. This positions nebokitug to potentially become the first FDA-approved treatment for PSC. Chemomab is on track to release clinical data from the SPRING trials open-label extension in Q1 2025. Discussions with potential strategic partners are ongoing, indicating a growth-positive outlook for the company.
Product StagePartners
growth-positive
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
Chemomab Therapeutics announced the successful completion of its End-of-Phase 2 Meeting with the FDA, aligning on a single Phase 3 registration study for nebokitug (CM-101) to treat primary sclerosing cholangitis (PSC). This marks a significant milestone as it provides regulatory clarity and positions nebokitug to potentially become the first FDA-approved treatment for PSC. The Phase 3 trial design does not require liver biopsies and is based on well-characterized clinical events associated with PSC disease progression. The company is in discussions with potential strategic partners and plans to launch the Phase 3 program by the end of the year.
Product StagePartners
growth-positive
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics, a clinical-stage biotechnology company, is advancing its CM-101 program, a monoclonal antibody targeting fibro-inflammatory diseases. The company has reported positive results from four clinical trials and is preparing for a Phase 3 trial in primary sclerosing cholangitis (PSC) following promising Phase 2 results. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations. Chemomabs management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, aiming to attract investor interest. The company anticipates achieving a clear FDA registrational pathway for the Phase 3 trial and reporting additional data in early 2025.
Product StageInvestmentFDA approved/pending approval
growth-positive
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics, a clinical-stage biotechnology company, is set to participate in Oppenheimers Movers in Rare Disease Summit on December 12, 2024, in New York City. The summit will feature panels, presentations, and one-on-one investor meetings. Chemomab will present an Elevator Pitch and engage with investors, highlighting its innovative therapeutics for fibro-inflammatory diseases, particularly its CM-101 monoclonal antibody. CM-101 has shown promise in treating primary sclerosing cholangitis (PSC) and systemic sclerosis, with positive results from clinical trials. The company anticipates FDA feedback and further data in early 2025. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment.
growth-positive
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab Therapeutics announced positive results from its Phase 2 SPRING trial for CM-101, a treatment for primary sclerosing cholangitis (PSC). The trial, presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2024, demonstrated that CM-101 has anti-fibrotic, anti-inflammatory, and anti-cholestatic effects. The study involved 76 patients and showed that CM-101 met its primary endpoint with a favorable safety profile. Secondary endpoints showed dose-dependent improvements in liver stiffness, ELF scores, and other biomarkers, particularly in patients with moderate to advanced disease. These results suggest that CM-101 could be a promising treatment for PSC, a disease with high unmet medical needs.
growth-positive
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics announced its financial and operating results for Q3 2024, highlighting significant progress in its CM-101 program for treating primary sclerosing cholangitis (PSC). The company plans to meet with the FDA in Q4 2024 to discuss the design of a Phase 3 trial for CM-101, following positive Phase 2 results. These developments are seen as a major clinical proof-of-concept for CM-101, potentially accelerating its path to market. Chemomab is also in discussions with potential strategic partners to further its clinical programs. The company has extended its cash runway to early 2026 and aims to launch the PSC registrational trial in late 2025.
Partners
growth-positive
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, is set to release its third-quarter 2024 financial results and provide a business update on November 14, 2024. The company is focused on developing innovative therapeutics for fibro-inflammatory diseases, with its lead product, CM-101, showing promising results in clinical trials. CM-101 is a monoclonal antibody targeting CCL24, a protein involved in fibrosis and inflammation. The company has reported positive outcomes from four clinical trials, including the Phase 2 SPRING trial for primary sclerosing cholangitis (PSC). Chemomab anticipates significant milestones in early 2025, including FDA feedback on a Phase 3 trial design and additional data from the SPRING trial. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC.
growth-positive
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, announced that its Phase 2 SPRING trial results for CM-101 in treating primary sclerosing cholangitis (PSC) will be presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2024. The trial showed improved fibrosis biomarkers in PSC patients, highlighting the potential of CM-101, a monoclonal antibody targeting CCL24, in treating fibro-inflammatory diseases. Chemomab has reported positive outcomes from four clinical trials of CM-101 and anticipates FDA feedback on its Phase 3 trial design in early 2025. The company has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC, indicating a promising future for its therapeutic developments.
growth-positive
Chemomab Therapeutics to Present at October 2024 Investor Conferences
Chemomab Therapeutics, a clinical-stage biotechnology company focused on fibro-inflammatory diseases, announced its participation in two upcoming investor conferences. Senior management will meet with investors at the Third Annual ROTH Healthcare Opportunities Conference in New York City on October 9, 2024, and CEO Dr. Adi Mor will participate in a fireside chat at the Maxim Healthcare Virtual Summit on October 16, 2024. The company has developed CM-101, a monoclonal antibody targeting CCL24, and has shown positive results in clinical trials. Chemomab expects significant milestones in early 2025, including FDA feedback on its Phase 3 trial design for primary sclerosing cholangitis.
Investment
growth-positive
Chemomab Therapeutics to Present at September 2024 Investor Conferences
Chemomab Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Dr. Adi Mor, will deliver corporate presentations at two significant events: the H.C. Wainwright 26th Annual Global Investment Conference and the HBM Biopharma Summit 2024. The presentations will highlight Chemomabs innovative therapeutics for fibro-inflammatory diseases, particularly their monoclonal antibody CM-101, which has shown positive results in multiple clinical trials. The H.C. Wainwright presentation will be webcast starting September 9, 2024, while the HBM Biopharma Summit presentation will occur live on September 23, 2024.
growth-positive
Chemomab jumps on positive liver scarring trial results
Chemomab Therapeutics, listed on Nasdaq, saw a significant stock price increase following the release of its second-quarter financial report and positive trial results for its treatment targeting rare liver scarring disease PSC. Despite a historical loss of over 90% of its value, the company is optimistic about its drugs potential, especially given recent FDA discussions about alternative trial indicators. The company plans to meet with the FDA later this year to finalize trial requirements. Investors include OrbiMed and Peter Thiel.
Investment
growth-positive
תוצאות הניסוי הקליני שהקפיצו את מניית חברת התרופות הישראלית
כמומאב תרפיוטיקס, אשר מוזגה לתוך השלד של אנקיאנו בתחילת 2021, ראתה עלייה של 14% במנייתה בעקבות פרסום דוחות הרבעון השני ותוצאות חיוביות מניסוי קליני. החברה מפתחת תרופות נגד מחלות המאופיינות בהצטלקות, ובחרה להתמקד במחלת הצטלקות הכבד הנדירה PSC. הניסוי הראה שינויים משמעותיים בסמנים ביולוגיים חשובים. החברה גייסה 45.5 מיליון דולר בהנפקה פרטית ב-2021 ועוד 10 מיליון דולר לאחרונה. החברה מתכננת להיפגש עם ה-FDA כדי לדון במבנה הניסוי שלב III. החברה נסחרת לפי שווי של 20 מיליון דולר.
InvestmentPublic TradingCustomers
growth-positive
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd. has reported positive results from its Phase 2 clinical trial for CM-101, a treatment for primary sclerosing cholangitis (PSC). The company also completed a PIPE financing round that included major new and existing investors, extending its cash runway through the beginning of 2026. The company is planning to advance CM-101 to a Phase 3 PSC trial and is in discussions with the FDA. The company also raised $10 million in a private placement in July 2024. The companys cash, cash equivalents, and short-term bank deposits were $12.8 million as of June 30, 2024.
Investment
Neutral
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that it will release its second quarter 2024 financial results and provide a business update on August 21, 2024. The company, which is developing innovative therapeutics for fibro-inflammatory diseases, has reported positive results from four clinical trials of its product, CM-101. The companys CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND.
Investment
growth-positive
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has announced the closure of a private placement that resulted in gross proceeds of approximately $10 million. The company sold a total of 8,097,167 ADSs and pre-funded warrants in lieu of ADSs. The private placement was participated by both existing and new investors including HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP. The funds will potentially extend the companys cash runway to the beginning of 2026. Chemomab is also in discussions with potential partners based on positive Phase 2 results.
Investment
growth-positive
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The company had previously been notified by Nasdaq in November 2023 that it was not in compliance as the closing bid price of the companys American Depositary Shares (ADSs) had been below $1.00 for more than 30 consecutive business days. However, from July 9, 2024 to July 22, 2024, the closing bid price of the ADSs was $1.00 or greater, leading to the regaining of compliance.
Public Trading
growth-positive
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. has reported positive topline results from the Phase 2 SPRING trial assessing its first-in-class monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis (PSC). The treatment achieved its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across a broad range of disease-related secondary efficacy endpoints. The company is planning to initiate a Phase 3 PSC trial in 2025 after interactions with the FDA. The company is also exploring opportunities to collaborate with strategic partners.
InvestmentExpand
growth-positive
Chemomab Therapeutics Announces $10 Million Private Placement
Chemomab Therapeutics Ltd. has announced a securities purchase agreement for a private investment in public equity (PIPE) that is expected to result in gross proceeds of approximately $10 million. The PIPE includes participation from both new investors, including HBM Healthcare Investments and Sphera Biotech Master Fund LP, and existing investors. The net proceeds from the PIPE will extend Chemomabs cash runway to fund its operations through the beginning of 2026. The company intends to use the net proceeds from the PIPE to fund its development programs for CM-101, and for general corporate purposes and working capital.
Investment
growth-positive
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has announced a new scientific publication that confirms the role of the soluble protein CCL24 in the pathologies underlying the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The study shows the potential of Chemomab’s CCL24-neutralizing antibody, CM-101, to interrupt the biological processes driving PSC disease progression and severity. The company expects to release topline data from the CM-101 PSC Phase 2 trial by mid-2024.
InvestmentExpand
growth-positive
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has reported on the anti-fibrotic activity of its drug CM-101. The company presented two scientific posters at the Annual Congress of the European Association for the Study of the Liver, and a poster presentation at the Gordon Research Conference on Chemotactic Cytokines. The presentations covered new preclinical studies and translational research supporting the clinical development of CM-101 for primary sclerosing cholangitis (PSC), a rare and often fatal liver disease. The company is expected to report topline data from the PSC clinical trial by mid-year 2024.
InvestmentExpand
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
growth-positive
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, has announced its financial and operating results for the first quarter ended March 31, 2024. The company reported an early completion of patient enrollment in its CM-101 Phase 2 trial in patients with primary sclerosing cholangitis (PSC) six months ahead of schedule. This has allowed the company to move up its topline readout to midyear 2024. The company also reported new peer-reviewed publications further validating the role of its CCL24 target and its CCL24-neutralizing antibody CM-101 in both PSC and systemic sclerosis (SSc).
Investment
growth-positive
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has been granted an additional 180-day compliance period by the Nasdaq Stock Market to regain compliance with Nasdaq’s minimum $1.00 bid price per share requirement. The company has until November 4, 2024, to meet this requirement. If the closing bid price of Chemomab’s American Depositary Shares is at least $1.00 per share for a minimum of 10 consecutive trading days, Nasdaq will confirm the companys compliance. This notification has no immediate effect on the listing or trading of the company’s shares.
Public Trading
Growth-Positive
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that its CEO, Dr. Adi Mor, will present at the Aegis Virtual Conference on May 7, 2024. The presentation will be webcast live. The company is known for developing innovative therapeutics for fibro-inflammatory diseases. It has reported positive results from three clinical trials of its product, CM-101, in patients, including a Phase 2a liver fibrosis trial in NASH patients and a study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024.
Management Changes
Growth-Positive
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that it will report its first quarter 2024 financial results and provide a business update on May 9, 2024. The company is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024.
Investment
growth-positive
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Chemomab Therapeutics Ltd. has announced the publication of a new study that validates CCL24 as a novel target for systemic sclerosis (SSc). The study was conducted by researchers at the University of Leeds and included over 200 patients. It found that one in four patients in a real-life SSc population had a high CCL24 serum concentration, despite standard of care treatment. The study also found that higher CCL24 levels were linked to the most severe forms of SSc. Chemomabs novel CCL24-neutralizing antibody CM-101 has potential as a treatment for SSc and is Phase 2-ready with an open US IND.
Investment
growth-positive
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on April 10, 2024. The event will feature clinical, academic and patient advocacy leaders discussing PSC disease management and evolving views on clinical development. The companys co-founder and CMO will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024. CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.
CustomersPartners
growth-positive
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab Therapeutics has been granted a new patent by the European Patent Office for the use of CM-101 in the treatment of multiple liver diseases, including primary sclerosing cholangitis (PSC). The patent extends the protections already in place for CM-101 in the U.S., Europe, Israel, and other territories. CM-101, a first-in-class monoclonal antibody, is currently being evaluated in a global Phase 2 trial for the treatment of PSC. The new patent provides additional intellectual property protection in key European markets. The company expects to release topline data from the Phase 2 PSC trial midyear 2024.
Expand
growth-positive
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
Chemomab Therapeutics, a clinical stage biotechnology company, has announced its financial and operating results for the full year and fourth quarter ended December 31, 2023. The company reported great progress in 2023, positioning it for potential major catalysts in 2024 and early 2025. The companys Phase 2 primary sclerosing cholangitis (PSC) trial was completed ahead of schedule, with topline data expected by mid-2024. The company also reported positive data from its Phase 2a clinical trial in patients with liver fibrosis. The companys cash runway has been extended to the end of the first quarter of 2025 due to effective financial management.
Management ChangesInvestment
Growth-Positive
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that CEO Dr. Adi Mor will present at the Leerink Partners Global Biopharma Conference in Miami, Florida from March 11-13, 2024. The presentation will be available on the investor relations section of the Chemomab website for 90 days. The company is developing innovative therapeutics for fibro-inflammatory diseases and has reported positive results from three clinical trials of CM-101 in patients. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024.
Management Changes
growth-positive
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
Chemomab Therapeutics Ltd, a clinical stage biotechnology company, has been granted new patents for CM-101 by the Patent Offices in Brazil and Israel. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that plays a critical role in diseases involving fibrosis and inflammation. The patents provide additional protections for the composition of CM-101 and its use in fibrotic diseases of the liver, including primary sclerosing cholangitis (PSC). The company has completed patient enrollment for the global Phase 2 SPRING trial for the treatment of PSC, with topline data expected by mid-2024.
Investment
Neutral
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has announced that it will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024. The company is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. It has reported positive results from three clinical trials of its CM-101 product in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury.
Growth-Positive
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that its CEO, Dr. Adi Mor, and other senior management members will participate in two upcoming investor conferences. These include the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the Leerink Partners Global Biopharma Conference. The company is focused on the discovery and development of therapeutics for fibro-inflammatory diseases. It has reported positive results from three clinical trials of its product, CM-101, in patients and expects topline data from a Phase 2 trial in mid-2024.
Management Changes
growth-positive
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has announced the publication of proteomic analyses that demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The studies reinforce the evidence showing that Chemomabs first-in-class CCL24-neutralizing antibody CM-101 can interrupt these destructive processes. The company is looking forward to the CM-101 Phase 2 topline readout expected midyear, which has the potential to deliver the first significant clinical proof-of-concept of CM-101s therapeutic activity in PSC.
InvestmentExpand
growth-positive
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, has announced the early completion of patient enrollment in its Phase 2 clinical trial for CM-101, a treatment for primary sclerosing cholangitis (PSC). The company expects to report topline data from the PSC clinical trial by mid-2024, earlier than previously projected. CM-101 is a first-in-class monoclonal antibody that neutralizes the soluble protein CCL24, which has been associated with key pathways underlying PSC pathophysiology. The drug has Orphan Drug designation for PSC in the U.S. and the European Union (EU) and was recently awarded Fast Track designation by the U.S. Food & Drug Administration (FDA).
Investment
Growth-Positive
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
Chemomab Therapeutics Ltd. has reported on its poster presentation at the American College of Rheumatology (ACR) Convergence 2023 conference. The study, conducted by Chemomab researchers in collaboration with academic scientists, analyzed serum samples and clinical data from patients with systemic sclerosis (SSc) to assess the effect of the soluble protein CCL24 on the pathogenesis of SSc. The companys first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes. The company has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.
InvestmentExpand
growth-positive
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its therapeutic candidate CM-101. The drug is being developed for the treatment of primary sclerosing cholangitis (PSC), a fibrotic liver disease. The Fast Track process is designed to expedite the development of new treatments for serious or life-threatening conditions with unmet medical needs. The companys Phase 2 SPRING trial for CM-101 is progressing towards completion of enrollment, with top-line results expected in the second half of 2024.
InvestmentExpand
growth-positive
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has presented new clinical data at AASLDs The Liver Meeting 2023. The data shows significant improvements in liver-related pathology pathways after treatment with CM-101. The companys first-in-class monoclonal antibody CM-101 is designed to neutralize CCL24 and normalize PSCs fibro-inflammatory disease processes. The company is advancing towards completion of patient enrollment in its Phase 2 PSC trial and expects a top-line data readout in the second half of next year. The company also presented data showing that CM-101 treatment led to significant downregulation in multiple immune-related pathways, along with an increase in metabolic pathways associated with improved glucose and fat metabolism.
InvestmentExpand
growth-positive
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, has reported its financial and operating results for Q3 2023. The company made significant progress in advancing its CM-101 Phase 2 PSC Trial towards completion of enrollment and expects topline readout in the second half of 2024. The companys cash and cash equivalents were $21.4 million as of September 30, 2023, compared to $26.7 million for the quarter ended June 30, 2023. The company expects its cash runway to last through year-end 2024. The net loss was $4.1 million for Q3 2023, compared to a net loss of $8.1 million for Q3 2022.
Investment
Growth-Negative
Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
Chemomab Therapeutics Ltd. has received a notice from the Nasdaq Listing Qualifications Department stating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company has until May 6, 2024, to regain compliance by having the closing bid price of its ADSs meet or exceed $1.00 per ADS for at least 10 consecutive business days. The notice has no immediate effect on the listing of the companys ADSs, which will continue to trade on the Nasdaq Capital Market under the symbol CMMB.
Public Trading
growth-positive
Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that it will release its third quarter 2023 financial results and a business update on November 9, 2023. The company is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. It has reported encouraging results from three clinical trials of its product, CM-101, in patients. The CM-101 program for the treatment of systemic sclerosis is Phase 2-ready and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
Investment
growth-positive
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that it will present at major U.S. scientific conferences in November 2023. The presentations will include an oral presentation on primary sclerosing cholangitis and a poster at the AASLD The Liver Meeting, as well as a poster presentation on the role of Chemomabs CCL24 target in manifestations of systemic sclerosis at the American College of Rheumatology Convergence. The company is focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Expand
growth-positive
Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that its CEO and CSO, Adi Mor, will discuss the CM-101 clinical program in primary sclerosing cholangitis (PSC) at the 2023 Roth MKM Healthcare Opportunities Conference. The companys first-in-class monoclonal antibody CM-101 is currently being assessed in the Phase 2 SPRING trial for the treatment of PSC, with topline data expected in the second half of 2024. Earlier this year, Chemomab reported positive results from a Phase 2a liver fibrosis trial in patients with nonalcoholic steatohepatitis (NASH). The companys ongoing PSC Phase 2 SPRING trial is evaluating two dose cohorts that are intended to provide high exposure to CM-101.
InvestmentExpand
growth-positive
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Chemomab Therapeutics Ltd., a clinical stage biotechnology company, announced that its CEO will present virtually at the H.C. Wainwright 25th Annual Global Investment Conference. The companys senior management will also be available for virtual one-on-one meetings with investors during the conference. Chemomab is developing innovative therapeutics for fibro-inflammatory diseases and has reported encouraging results from clinical trials of CM-101, a monoclonal antibody designed to treat such diseases. The company is currently conducting a Phase 2 trial in primary sclerosing cholangitis patients, with topline data expected in the second half of 2024.
InvestmentManagement Changes
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
growth-positive
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
Chemomab Therapeutics has announced the publication of a peer-reviewed research article that highlights the key role of CCL24 in primary sclerosing cholangitis (PSC), a rare fibro-inflammatory disease. The article describes how CM-101, Chemomabs CCL24-neutralizing antibody, can interrupt the fibro-inflammatory processes that lead to PSC and potentially improve patient outcomes. CM-101 is currently in a Phase 2 trial for the treatment of PSC. The publication provides comprehensive data supporting the therapeutic potential of blocking CCL24 with CM-101 to reduce liver inflammation, fibrosis, and cholestasis in PSC patients. The topline results of the PSC clinical trial are expected next year. The article also mentions the involvement of prominent academic groups in producing the data and the collaboration with Douglas Thorburn, MD, who is the Principal Investigator for the CM-101 Phase 2 PSC trial.
Customers
growth-positive
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
Chemomab Therapeutics presented scientific posters at EASL 2023, providing further evidence for the potential of CM-101 as a treatment for primary sclerosing cholangitis (PSC). The posters discussed the relationship between CM-101s target, CCL24, and PSC disease pathways, as well as the clinical design and endpoints of Chemomabs ongoing Phase 2a trial of CM-101 in PSC patients. The data presented supports the role of CCL24 in PSC and its associated pathways, and demonstrates the ability of CM-101 to interrupt fibrotic and inflammatory disease processes. Chemomab is optimistic about the potential of CM-101 as a therapy for PSC, which currently lacks effective treatments. The company expects to release topline results from the Phase 2a trial in the latter half of 2024.
CustomersPartners
growth-positive
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
Chemomab Therapeutics reported positive data from a secondary analysis of its Phase 2a liver fibrosis trial in NASH patients. The data showed improvements in additional biomarkers of fibrosis and inflammation, reinforcing the positive clinical results previously released. The treatment with CM-101, the companys CCL24-neutralizing antibody, resulted in greater biomarker response in NASH patients at greater risk of disease progression. The results are encouraging and support CM-101s direct anti-inflammatory and anti-fibrotic dual mode of action. The company is also conducting a Phase 2 trial of CM-101 in primary sclerosing cholangitis (PSC) patients. The trial involves higher doses of CM-101 and aims to evaluate its impact on biomarkers associated with inflammation and fibrogenesis in PSC patients.
Customers
growth-positive
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
Chemomab Therapeutics has announced changes to its executive leadership team. Adi Mor has been reappointed as CEO, replacing Dale Pfost, while Sigal Fattal has been reappointed as CFO, replacing Donald Marvin. Nissim Darvish has been appointed Chairman of the Board, replacing Dr. Pfost. The company is implementing cost-reduction measures to extend its cash runway to the end of 2024. Chemomab is focused on the discovery and development of therapeutics for fibrotic and inflammatory diseases. They are currently conducting a Phase 2 trial for CM-101, their anti-CCL24 antibody, in primary sclerosing cholangitis patients. The company has reported positive results from a Phase 2 liver fibrosis study in NASH patients and an investigator study in patients with severe lung injury.
Management Changes
growth-positive
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
Chemomab Therapeutics presented new patient data at the 2023 European Congress of Rheumatology, highlighting the role of CCL24 in fibrotic disease pathology and prognosis. The study showed that high serum concentration levels of CCL24 were correlated with the severity of systemic sclerosis (SSc), including a higher incidence of fibrosis-associated symptoms, increased risk of interstitial lung disease progression, and shorter SSc-related survival time. The results support the therapeutic rationale for Chemomabs CCL24-neutralizing antibody CM-101 as a potential treatment for SSc and other fibrotic diseases. The company is focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases. The article does not mention any specific customers, investors, or acquisition amounts. The date of the event described in the article is May 31-June 3, 2023.
Customers
growth-positive
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
Chemomab Therapeutics announced upcoming CM-101 data presentations at major European scientific conferences in June 2023. The presentations will highlight the companys unique approach to fibro-inflammatory diseases and provide details of their clinical programs and clinical data. The presentations will be given by respected opinion leaders who support the clinical development of CM-101, a therapy that targets both inflammation and fibrosis.
Partners
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
growth-positive
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
Chemomab Therapeutics will participate in scientific conferences in April and May. The company is focused on the discovery and development of therapeutics for fibro-inflammatory diseases. They will present research on CCL24 serum concentration and its role in systemic sclerosis at the British Society for Rheumatology Annual Conference. They will also present data on the proinflammatory role of CCL24 in cholestatic disease at the EASL Monothematic Conference on Biliary Fibrosis. Additionally, Chemomabs corporate development team will attend the BIO International Conventions One-on-One Partnering event in Boston. Chemomab is currently conducting Phase 2 trials for CM-101 in NASH and severe lung injury patients, with trials in primary sclerosing cholangitis and systemic sclerosis expected to begin soon.
PartnersExpand
Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update
Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023
Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update
growth-positive
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, has announced that its management will be presenting a corporate overview and participating in one-on-one meetings at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The conference will be held virtually. Chemomab is focused on the discovery and development of therapeutics for fibro-inflammatory diseases. The companys lead product, CM-101, is a monoclonal antibody designed to bind and block CCL24 activity, which promotes fibrosis and inflammation.
Management Changes
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
growth-positive
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis
Chemomab Therapeutics, a clinical-stage biotech company, has announced that an independent Data Monitoring Committee (DMC) has completed a safety review of the companys ongoing Phase 2 trial of lead product CM-101 in primary sclerosing cholangitis (PSC) patients. The DMC had no safety concerns with proceeding with adding a planned 20 milligram per kilogram (mg/kg) dosing cohort to the PSC trial. The company plans to report top-line results from this trial in the coming weeks.
Investment
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19
Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update
growth-positive
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities
Chemomab Therapeutics, a clinical-stage biotechnology company, has announced the appointment of Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development. The company is preparing to report topline results from its Phase 2 trial in liver fibrosis patients later this year, and is expanding its Phase 2 trial of CM-101 in primary sclerosing cholangitis. It will also soon be launching a Phase 2 biological proof of concept trial in systemic sclerosis, and is assessing potential new indications for CM-101 in other fibro-inflammatory disorders.
Management ChangesExpand
growth-positive
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Chemomab Therapeutics, a clinical-stage biotechnology company, has announced its financial and operating results for Q2 2022. The company has made progress on multiple fronts, including advancing clinical programs for CM-101, a first-in-class monoclonal antibody, adding to its intellectual property portfolio, presenting new data at scientific meetings, and hiring experienced staff. The company also gained a new U.S patent for the use of CM-101 in liver diseases. Chemomab concluded the treatment phase of its Phase 2 liver fibrosis trial and plans to enroll a total of 93 patients for its Phase 2 trial in Primary Sclerosing Cholangitis patients.
InvestmentManagement Changes
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
growth-positive
Chemomab Awarded New U.S. Patent for CM-101, Its First-in-Class CCL24 Neutralizing Antibody
Chemomab Therapeutics has been granted a new patent for CM-101, its monoclonal antibody for the treatment of liver diseases. The patent covers the use of CM-101 and sequence-related antibodies for the treatment of hepatic diseases. CM-101 is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis. The new patent provides additional protections for Chemomabs current clinical programs and future liver disorder treatments. The patent has a filing date of March 8, 2018, and a grant date of June 21, 2022. Chemomab is a clinical stage biotechnology company focused on developing therapeutics for fibrotic and inflammatory diseases.
CustomersPartners
growth-positive
Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022
Chemomab Therapeutics, Ltd. is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases. They have reported data supporting the role of CCL24 as a therapeutic target for systemic sclerosis (SSc) at the EULAR European Congress of Rheumatology. Chemomabs CCL24-neutralizing antibody, CM-101, is expected to enter a Phase 2 trial in systemic sclerosis later this year. The study examined the role of CCL24 in systemic sclerosis patient cohorts and found elevated serum levels of CCL24 in patients with the disease. High CCL24 levels were correlated with disease activity and worse prognosis. Chemomab plans to open clinical study sites in Europe and the U.S. for the Phase 2 trial.
Expand
growth-positive
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Chemomab Therapeutics has appointed Dale R. Pfost as CEO, reflecting a planned strategic expansion of the senior management team. Dr. Adi Mor, the current CEO, will continue as Chief Scientific Officer and a member of the Board of Directors. Dr. Pfost brings over 30 years of experience as a life science executive and investor. The company is focused on the discovery and development of therapeutics for inflammatory and fibrotic diseases. Chemomab is currently conducting Phase 2 studies and plans to leverage strategic growth opportunities. Dr. Pfosts appointment is subject to shareholder approval.
Management ChangesExpand
growth-positive
Chemomab Completes Merger with Anchiano Therapeutics
Chemomab Ltd. has completed its merger with Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. The company has secured $45.5 million in financing through a private investment in public equity (PIPE) led by new and existing investors. The funds will be used to advance clinical trials for its lead product, CM-101, and further develop its pipeline. Chemomab plans to enroll patients in Phase 2 trials for rare fibrotic conditions and expects clinical readouts in 2021-2022. The company has also entered into an agreement to sell Anchianos preclinical RAS programs to Kestrel Therapeutics Inc. for $1 million. Chemomabs CEO, Dr. Adi Mor, expressed confidence in the companys progress and its ability to accelerate clinical programs. The merger has resulted in a 4:1 reverse split of ordinary shares and increased the number of ordinary shares per ADS. Chemomab shareholders now own approximately 90% of the combined company.
AcquisitionPublic TradingInvestmentManagement Changes
growth-positive
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
Anchiano Therapeutics and Chemomab have announced that Anchianos shareholders have approved the merger with Chemomab and the issuance of Anchiano American Depositary Shares (ADSs) in connection with the merger. The companies have also secured a private investment of $45.5 million into the combined company, led by new and existing investors of Chemomab. The private financing consists of the sale of ADSs and accompanying warrants. The merger and private placement are expected to support the advancement of Chemomabs pipeline. Anchiano is a biopharmaceutical company focused on targeted cancer therapies, while Chemomab is a clinical-stage biotech company developing therapeutics for fibrosis-related diseases.
AcquisitionInvestment
growth-positive
Chemomab Announces First Patient Enrolled in Phase IIa Study of CM-101 for the Treatment of Patients with Primary Sclerosing Cholangitis
Chemomab Ltd. has enrolled the first patient in a phase IIa clinical trial of CM-101 for the treatment of primary sclerosing cholangitis (PSC). The study aims to evaluate the safety and efficacy of CM-101 in adult subjects with PSC over 15 weeks. CM-101 is a monoclonal antibody platform that shows promise in treating fibrosis-related diseases. Chemomab is collaborating with clinical sites such as the Royal Free Hospital in London to establish proof-of-concept for CM-101s activity in treating PSC. The company is focused on developing innovative therapeutics for fibrosis-related diseases and is supported by investors including OrbiMed and Peter Thiel. Chemomab has also entered into a merger agreement with Anchiano Therapeutics Ltd., which will create a public company focused on advancing CM-101 for the treatment of fibrosis-related diseases.
Customers
growth-positive
Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
Chemomab Ltd., a clinical-stage biotech company, has announced positive results from its phase Ib clinical trial of CM-101, a treatment for nonalcoholic fatty liver disease. The trial found that repeated administrations of CM-101 were safe and well-tolerated, and showed beneficial effects on fibrotic and fibrogenesis markers. The company plans to use this data to support the planning of phase II studies. Chemomab recently entered into a merger agreement with Nasdaq-listed company Anchiano Therapeutics Ltd., which will result in a public company focused on advancing CM-101.
Acquired-by
growth-negative
Anchiano Therapeutics jumps after Chemomab merger
Anchiano Therapeutics Ltd. is merging with Chemomab Ltd. to create a company focused on advancing Chemomab’s lead product, CM-101, for the treatment of fibrosis-related diseases. Anchiano had been developing a cancer treatment that did not meet its end targets in clinical trials. The merger has resulted in a rise in Anchianos share price, but it is still below its market cap in 2019. Chemomab will seek to complete a private placement financing to advance CM-101 into Phase II clinical trials in rare fibrotic indications. The merged company also plans to evaluate CM-101s anti-fibrotic effect in patients diagnosed with non-alcoholic steatohepatitis (NASH).
AcquisitionExpand
growth-positive
Chemomab Announces Late-Breaking Presentation of CM-101 First Evidence of Anti-Fibrotic Activity in NAFLD Patients at the AASLD's The Liver Meeting Digital Experience™ 2020
Chemomab Ltd., a clinical-stage biotech company, will present clinical data from its phase Ib study of CM-101 in non-alcoholic fatty liver disease (NAFLD) patients at The Liver Meeting Digital Experience™ 2020. The data shows that CM-101, a CCL24 neutralizing antibody, decreased serum biomarkers of fibrosis and inflammation with an excellent safety profile and tolerability. This confirms CM-101s anti-fibrotic activity and its potential as a treatment for fibrosis-related diseases. Chemomab will also present safety and target engagement data from its phase I study of CM-101 in healthy volunteers. Chemomab is supported by lead investors OrbiMed and Thiel Capital.
CustomersPartners
growth-positive
Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
Chemomab Ltd. has received Orphan Drug Designation (ODD) from the European Commission for its lead drug candidate CM-101 for the treatment of Primary Sclerosing Cholangitis (PSC). The ODD designation is a positive regulatory milestone that facilitates and accelerates the clinical development of drugs for rare diseases. Chemomab believes that CM-101 has the potential to become a transformative treatment for PSC patients. The company plans to advance CM-101 through a Phase 2a clinical trial starting in Q3 2020. Chemomab is a privately held company supported by lead investors OrbiMed and Thiel Capital.
Customers
growth-positive
Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis
Chemomab Ltd. has received regulatory approvals to commence a Phase IIa clinical trial for CM-101 as a treatment for Primary Sclerosing Cholangitis (PSC). The trial will evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC. Chemomab is generating enthusiasm from clinical research partners and aims to provide effective treatment options for PSC patients. The company plans to start the clinical trial in the near future.
Investment
growth-positive
ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio
ChemomAb Ltd. has been granted a composition of matter patent for CM-101, a monoclonal antibody targeting fibrosis-related diseases. The patent has been granted by the Patent and Trademark Offices of the United States, Japan, and China. The patent provides intellectual property protection for CM-101 until at least 2035, with a possible extension of up to five years. ChemomAb plans to initiate Phase II clinical trials for CM-101 in Primary Sclerosing Cholangitis, Systemic Sclerosis, and NASH. The grant of the patent strengthens the companys strategic position and supports various commercial opportunities. ChemomAbs lead investors include OrbiMed and Thiel Capital.
Investment
growth-positive
ChemomAb Ltd., Announces Data from Phase 1 Study of CM-101 Subcutaneous Formulation Demonstrating Comparable Exposure to The Intravenous CM-101 Formulation
ChemomAb Ltd., a clinical-stage biopharmaceutical company, has announced the results of its Phase 1 study evaluating the subcutaneous (SC) formulation of CM-101 in healthy volunteers. The data showed that similar dose levels of the SC and IV formulations yielded a comparable exposure, half-life, safety, tolerability and target engagement. The company intends to use the data to explore multiple administrations of CM-101 in non-alcoholic steatohepatitis (NASH) patients using the SC formulation. The companys lead investors include OrbiMed and Peter Thiel.
Investment
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
growth-positive
Led by OrbiMed Israel and Peter Thiel, ChemomAb Raises $10 Million in Series B Funding
ChemomAb, a bio-pharmaceutical start-up, has completed a $10 million fund raising round led by OrbiMed Israel and Peter Thiel. The investment will enable the company to move forward with its clinical program for the treatment of non-alcoholic fatty liver disease (NASH) and support the development of the product for additional fibrotic orphan indications. ChemomAbs leading product, a monoclonal antibody, is currently in phase 1 clinical trials in Israel. The company aims to develop a breakthrough product for the treatment of fibrotic and inflammatory diseases.
Investment
Chemomab Therapeutics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 19 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 9 classification IDs that could be used for matching.
Chemomab Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 514672625 |
| Crunchbase | chemomab |
| Phone | +972773310156 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-09-29T00:00:00.000Z |
| Created | 2017-12-04T00:00:00.000Z |
| Status detail | Public on NASDAQ on Mar, 2021<br> |